Hangzhou Yunbai Pharmaceutical Technology

Hangzhou Yunbai Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of innovative small molecule drugs for metabolic and inflammatory diseases. The company's primary focus is on the incretin pathway, specifically developing next-generation oral small molecule GLP-1 receptor agonists to treat obesity and type 2 diabetes. Its lead candidate, YB-211, is designed to offer improved patient convenience and efficacy compared to injectable biologics. Yunbai Pharma leverages a robust internal research platform and is supported by leading venture capital investors including Qiming Venture Partners and IDG Capital. The company aims to address significant unmet medical needs in the global healthcare market by providing accessible oral alternatives for chronic metabolic conditions.